Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 35 results found. Search for [ pfizer UK rollout ]

Results 1 to 21 of 35
Joe C Mathew
March 3, 2021
Over 110 million doses of this to about 60 countries will be met through the AstraZeneca (AZ)-Serum Institute of India partnership


Reuters
February 20, 2021
New Zealand expects its nationwide rollout covering the country's population of 5 million will take a full year, while Australia aims to inoculate its 25 million citizens by October


Reuters
February 8, 2021
Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75%, researchers said


Joe C Mathew
January 7, 2021
Fact sheets for recipients of Moderna and Pfizer-BioNTech vaccines in US and UK clarify that the vaccines are yet to be fully approved; recipients have been asked to get help if they experience severe side effects or allergic reactions


Reuters
January 4, 2021
Scientists say the new South African variant has multiple mutations in the important \"spike\" protein that the virus uses to infect human cells


PTI
January 4, 2021
Brian Pinker is among the first to be vaccinated by the Oxford University Hospital's (OUH) chief nurse, hailed as a major milestone in the phased vaccination programme being undertaken by the NHS


Reuters
January 4, 2021
Moncef Slaoui, head of Operation Warp Speed, the federal vaccine program, said on CBS' \"Face the Nation\" that officials were in talks with Moderna and the Food and Drug Administration about the idea


PTI
January 2, 2021
While AstraZeneca says it expects 2 million doses of the Oxford University vaccine to be ready each week in just over a fortnight, Pfizer BioNTech said the number of doses it has now sent to the UK is 'in the millions'


BusinessToday.In
January 2, 2021
Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally


BusinessToday.In
January 1, 2021
CDSCO's expert panel has recommended the Serum Institute of India's Covishield COVID-19 vaccine for emergency use authorisation to DCGI


Manoj Sharma
December 31, 2020
Suffering poor financial health, Central government has not given a concrete answer on who will bear the cost of vaccinating Indians - Centre, states, or the people themselves


PTI
December 27, 2020
Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine


Reuters
December 24, 2020
Brazil is the first country to complete a late-stage trial of the vaccine, called CoronaVac, but a release of the results, first set for early December, has now been delayed three times


BusinessToday.In
December 24, 2020
World's biggest vaccine maker has already manufactured over 50 million doses; further production will start as soon as it gets necessary approvals in India and the UK. SII is hoping to supply 3 billion doses of vaccine in 2021


PTI
December 19, 2020
Authorisation by the MHRA will also give confidence to countries across the world. India has already manufactured more than 50 million of the AstraZeneca vaccines, the newspaper notes


BusinessToday.In
December 17, 2020
The shots for Sputnik V are available for free for those in medical and educational facilities, whether owned by the state or privately. Social and municipal workers, retail and service workers, and those in the arts can also get the shots at no cost


BusinessToday.In
December 15, 2020
A senior official from WHO told Reuters about its talks with both companies to include their coronavirus vaccines as part of an early global rollout


Reuters
December 13, 2020
The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States


BusinessToday.In
December 11, 2020
GSK said phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years but there was an insufficient response in older adults


BusinessToday.In
December 9, 2020
India Stock Market Highlights Today: Intraday, both indices touched all time highs today, with Sensex hitting 46,164 and Nifty touching 13,548.


PAGES 1 OF 2  12